Stock PRLD PRELUDE THERAPEUTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

All News Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
3.73 USD -8.35% Intraday chart for Prelude Therapeutics Incorporated -3.37% -12.65%
05-07 Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-10 Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
GL
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated
CI
Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes
CI
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
GL
Transcript : Prelude Therapeutics Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM
JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target
MT
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
GL
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
GL
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5
MT
Prelude Therapeutics Shares Surge Following Shelf Registration
MT
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
GL
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Prelude Therapeutics Incorporated - Special Call
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10
MT
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index
CI
Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding
CI
Prelude Therapeutics Announces $25 Million Private Placement
GL
Prelude Therapeutics Incorporated : Announces $25 Million Private Placement - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRLD Stock
  4. News Prelude Therapeutics Incorporated
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW